PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2007-08-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT00141401
Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-08-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1561
- Registration Number
- NCT00141193
- Locations
- ๐บ๐พ
Pfizer Investigational Site, Montevideo, Uruguay
US Inhaled Insulin Therapeutic Choice Questionnaire Study
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2007-03-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 740
- Registration Number
- NCT00139763
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Parecoxib In Post Surgery (Hemicolectomy) Pain
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2009-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00139607
- Locations
- ๐ฎ๐น
Pfizer Investigational Site, Siena, Italy
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 600
- Registration Number
- NCT00139750
- Locations
- ๐ฏ๐ต
Pfizer Investigational Site, Ohita, Japan
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2011-05-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 606
- Registration Number
- NCT00140075
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT00140023
- Locations
- ๐ต๐ญ
Pfizer Investigational Site, Quezon City, Philippines
Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-04-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 329
- Registration Number
- NCT00140062
- Locations
- ๐ธ๐ช
Pfizer Investigational Site, Uppsala, Sweden
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 410
- Registration Number
- NCT00139698
- Locations
Pfizer Investigational Site
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 288
- Registration Number
- NCT00139659
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Neuss, Germany
ยฉ Copyright 2024. All Rights Reserved by MedPath